Autopsy report · NCT00064636
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Cause of deathNo reason given
Life of this trial
- Registered 7 months after it had already started.
- 46 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Advanced Non-Small Cell Lung Cancer; Other Solid Tumors
- Interventions
- VELCADE TM (bortezomib) for Injection, or PS-341
- Participants
- 46
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.